Sugen (SUGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Neal davidson who wrote (454)	5/31/1999 11:45:00 PM
From: Miljenko Zuanic	Read Replies (1) of 550

Maybe not! <<They also ''emphasize an important potential side-effect of anti-VEGF treatment and, possibly, other anti-angiogenic therapies in patients of pediatric age, when the growth plate undergoes active remodeling.''>> THis studies at UCSF/GNE are related to VEGF-MAb, not specific receptor, so what if different receptor than Flk-1 is involved in cartilage/bone transformation or growth??? I am not promoting that it is, but also it is speculative to extrapolate other drugs side effects (with different target) to this observation in mice which is related to circulating VEGF. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next